«We anticipate,» says Dr. Chou, «that this research will provide important pre-clinical data to support clinical trials using DAC and similar drugs combined with immune therapies targeting antigens like NY - ESO - 1 to treat advanced colorectal cancer and
potentially other common cancers.»